Ironwood Pharmaceuticals, Inc. - Class A

Day range

$3.45 – $3.54

Open

$3.49

Prev close

$3.46

Volume

589.84K

Market cap

$571.73M

Shares out

165.24M

P/E

4.40

P/S

1.47

P/B

-3.53

P/FCF

3.08

ROE

-80.2%

ROA

45.6%

Debt/Equity

-2.38

Div yield

0.00%

As of Oct 23, 2026

• Executive compensation changeOct 16, 2026

  The Company intends to enter into an amended and restated executive severance agreement with Ms. Gaskins, effective as of the Transition Date, in connection with her appointment as the Company's Chief Executive Officer.

• Annual meeting resultsJun 18, 2026

  The stockholders elected eight director nominees, each to serve on the board of directors of the Company for a one-year term extending until the 2027 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified, or until his or her death, resignation or removal, based on the following votes: [detailed voting results for Mark Currie, Alexander Denner, Jon Duane, Marla Kessler, Thomas McCourt, Julie McHugh, Catherine Moukheibir, and Jay Shepard].

• Debt retirementJun 15, 2026

  On June 15, 2026, Ironwood Pharmaceuticals, Inc. (the "Company") repaid in full the $200.0 million aggregate principal amount of its 1.50% convertible senior notes due 2026 (the "2026 Convertible Notes") at their scheduled maturity.

• Cfo departureMay 13, 2026

  On May 8, 2026, Gregory Martini notified Ironwood Pharmaceuticals, Inc. (the "Company") that he is resigning from his position as Senior Vice President, Chief Financial Officer, effective May 15, 2026. Mr. Martini's resignation is not due to any disagreement with the Company on any matter relating to the Company's financial reporting.

• Settlement agreementDec 23, 2025

  In connection with entry into the Amendment, on December 18, 2025, VectivBio and the Company entered into a settlement agreement and release pursuant to which VectivBio and Ferring have settled all claims between the parties arising out of Ferring's complaint captioned Ferring International Center S.A. v. VectivBio AG 2:25-cv-01001 brought in the United States District Court for the Eastern District of Texas.

• ABBVABBVIE INC.+0.14%

Days to cover

6.2

Short interest

15.57M

Avg volume

2.52M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Will Linzess Continue to Aid Ironwood's Top-Line Growth in Q3?
  positiveZacks Investment Research· Oct 7, 2026
• PGEN vs. IRWD: Which Biotech Stock Offers Better Growth Potential?
  positiveZacks Investment Research· Sep 30, 2026
• 3 Stocks Trading Near $5 With Massive Earnings Upside
  positiveInvesting.com· Feb 9, 2026
• Stock Market Today: S&P 500, Nasdaq, WTI Crude Futures Advance After US Strike On Venezuela— GH Research, Vertiv Holdings, Nukkleus In Focus (UPDATED)
  positiveBenzinga· Jan 5, 2026
• Ironwood Finds a New Floor as LINZESS Net Pricing Turns Into a Growth Lever
  positiveInvesting.com· Jan 2, 2026